• Through ongoing quality and accounting reviews, Dexcom discovered two lots of scrapped product were stolen by a third party before destruction and sold into the market.
  • Dexcom is working closely with the FDA and other authorities to ensure patient safety and to investigate the crime.

DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, announced today through ongoing quality and accounting reviews it recently identified certain lots of Dexcom G7 sensors originally designated as scrap and intended for destruction were stolen during the destruction process, then sold by third parties.

Scrapping limited amounts of sensors that do not meet Dexcom standards is a routine part of the company's quality control process. Sensors identified as scrap are sent to a third-party vendor for destruction and recycling.

At this time, Dexcom has identified two lots of Dexcom G7 sensors (1725204004 and 1725069002) that were stolen, sold and used by some customers.